Share
+1
Share

Article

April 5, 2018

Avatar

Tiash Saha
1483 views
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?
Categories: BRIEFING, DRUG TRIAL, NEWLY PUBLISHED
Tags: , , , ,
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Get 1-Month Free Subscription

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?

More in BRIEFING

BRIEFING

First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

BRIEFING

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

BRIEFING

AstraZeneca Spinout Viela Bio Fetches $250 M, Pushes Pipeline Autoimmune Drugs in Clinical Study

AstraZeneca subsidiary, MedImmune has spun out a new inflammation- and autoimmunity-focused biotech, Viela Bio with six molecules from MedImmune. The ...

BRIEFING

FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone

US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. ...

Most Popular

GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.